What is he best known for?
The fields of study he is best known for:
- Enzyme
- Organic chemistry
- Biochemistry
Alexandros Makriyannis mainly focuses on Cannabinoid, Cannabinoid receptor, Pharmacology, Endocannabinoid system and Receptor.
Alexandros Makriyannis combines subjects such as Agonist, Antagonist, Cannabinoid receptor type 2, Stereochemistry and Anandamide with his study of Cannabinoid.
His research in Cannabinoid receptor intersects with topics in Endocrinology and Inverse agonist.
His Pharmacology research includes elements of AM251, Rimonabant, Hippocampal formation, Cannabinoid Receptor Agonists and In vivo.
His work is dedicated to discovering how Endocannabinoid system, Fatty acid amide hydrolase are connected with Neuroprotection and other disciplines.
His Receptor research includes themes of Inflammation, Neurochemical, Endogeny and Central nervous system.
His most cited work include:
- Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors (1223 citations)
- Functional role of high-affinity anandamide transport, as revealed by selective inhibition. (735 citations)
- Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS (435 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Cannabinoid, Cannabinoid receptor, Pharmacology, Stereochemistry and Endocannabinoid system.
The Cannabinoid study combines topics in areas such as Agonist, Endocrinology, Antagonist and Cannabinoid receptor type 2.
His Cannabinoid receptor research is multidisciplinary, incorporating elements of Neuroscience and Ligand.
His studies in Pharmacology integrate themes in fields like AM251, Cannabinoid receptor antagonist, Rimonabant, Inverse agonist and In vivo.
His Stereochemistry study incorporates themes from Biological activity, Structure–activity relationship, Ring and Chemical synthesis.
The various areas that Alexandros Makriyannis examines in his Endocannabinoid system study include Endogeny and Fatty acid amide hydrolase.
He most often published in these fields:
- Cannabinoid (44.52%)
- Cannabinoid receptor (40.10%)
- Pharmacology (33.88%)
What were the highlights of his more recent work (between 2014-2021)?
- Pharmacology (33.88%)
- Cannabinoid (44.52%)
- Cannabinoid receptor (40.10%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Pharmacology, Cannabinoid, Cannabinoid receptor, Endocannabinoid system and Receptor.
His Pharmacology research is multidisciplinary, relying on both In vivo, Inverse agonist, Antagonist, Rimonabant and Nicotine.
The concepts of his Cannabinoid study are interwoven with issues in Agonist and Antagonism.
His biological study spans a wide range of topics, including Neuropathic pain and Stereochemistry.
His Cannabinoid receptor study combines topics in areas such as Endocrinology and Neuroscience.
His study explores the link between Endocannabinoid system and topics such as Fatty acid amide hydrolase that cross with problems in Anandamide, URB597 and Neuroprotection.
Between 2014 and 2021, his most popular works were:
- Crystal Structure of the Human Cannabinoid Receptor CB2. (310 citations)
- Crystal structures of agonist-bound human cannabinoid receptor CB1 (209 citations)
- A new antibiotic selectively kills Gram-negative pathogens (105 citations)
In his most recent research, the most cited papers focused on:
- Enzyme
- Organic chemistry
- Biochemistry
Alexandros Makriyannis mainly investigates Pharmacology, Endocannabinoid system, Cannabinoid, Cannabinoid receptor and Rimonabant.
His study in Pharmacology is interdisciplinary in nature, drawing from both Cannabinoid receptor type 1, Fatty acid amide hydrolase, Opioid and Cannabinoid receptor type 2.
His research integrates issues of Endocrinology, Arachidonic acid and Linoleic acid in his study of Endocannabinoid system.
Alexandros Makriyannis is investigating Cannabinoid receptor as part of his Receptor and Agonist and Cannabinoid receptor study.
Alexandros Makriyannis works mostly in the field of Receptor, limiting it down to concerns involving Signal transduction and, occasionally, HEK 293 cells.
The study incorporates disciplines such as Cannabinoid receptor antagonist, Inverse agonist and Nicotine in addition to Rimonabant.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
